[CUSIP No.64110W102 13G Page 2 of18 Pages 1 NAMES OF REPORTING PERSONS Lone Spruce, L.P. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP o (a) x (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH]
[____________________ FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts ___________________ iSoftStone Holdings Limited (Exact name of issuer of deposited securities as specified in its charter) n/a Cayman Islands (Jurisdiction of incorporation or organization of issuer) JPMORGAN CHASE BANK, N.A. (Exact name of depositary as specified in its charter) 1 Chase] [(1) Issuance and Pre-Release of ADSs. 2 (2) Withdrawal of Deposited Securities. (3) Transfers of ADRs. provided provided 3 (4) Certain Limitations. provided (5) Taxes. 4] [Ziegler, Ziegler & Associates LLP Counselors at Law th 570 Lexington Avenue, 44 New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 November 7, 2011 JPMorgan Chase Bank, N.A., as Depositary 1 Chase Manhattan Plaza, Floor 21 New York, New York 10005 American Depositary Shares evidenced by American Depositary Receipts for deposited ordinary shares of iSoftStone Holdings Limited Dear] [Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A. represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (iSoftStone Holdings Limited 333-170867) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time]
[The Staffs comment is noted, and the Company will include disclosure in Item 5 of its annual report on Form20-F for the year ending December31, 2011 regarding the need to accrue and pay withholding or other taxes if funds are repatriated and the Companys current plans with respect to repatriation of funds.]
[Company Contact FOR RELEASE ON NOVEMBER 7, 2011 AT 4:20 p.m. EST (New York) China Biologic Reports Third Quarter 2011 Results TAI'AN, Shandong Province, China, November 7, 2011 China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), one of the leading plasma-based biopharmaceutical companies in the Peoples Republic of China (PRC), today reported its financial results for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 7, 2011 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]
[The Staffs comment is noted, and the Company will include disclosure in Item 5 of its annual report on Form20-F for the year ending December31, 2011 regarding the need to accrue and pay withholding or other taxes if funds are repatriated and the Companys current plans with respect to repatriation of funds.]
[Company Contact FOR RELEASE ON NOVEMBER 7, 2011 AT 4:20 p.m. EST (New York) China Biologic Reports Third Quarter 2011 Results TAI'AN, Shandong Province, China, November 7, 2011 China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), one of the leading plasma-based biopharmaceutical companies in the Peoples Republic of China (PRC), today reported its financial results for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 7, 2011 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]
[Mindray Announces Third Quarter 2011 Financial Results Shenzhen, China November7, 2011 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September30, 2011. Highlights for Third Quarter 2011 - Net revenues were $218.4 million, up 29.8% over] [Mindray Announces Up to $100 Million Share Repurchase Program Shenzhen, China November7, 2011 Mindray Medical International Limited (Mindray ormpany, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has approved a share repurchase program. The share repurchase program is authorized to be in effect through]
[FORM 10-Q (Mark One) For the quarterly period ended: September 30, 2011 For the transition period from ____________ to _____________ CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 14 East Hushan Road Taian City, Shandong 271000 Peoples Republic of China (+86) 538-620-2306 _____________________________________________________ Yes [X] No [ ] Yes] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. (Principal Financial Officer)]
[FORM 10-Q (Mark One) For the quarterly period ended: September 30, 2011 For the transition period from ____________ to _____________ CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 14 East Hushan Road Taian City, Shandong 271000 Peoples Republic of China (+86) 538-620-2306 _____________________________________________________ Yes [X] No [ ] Yes] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. (Principal Financial Officer)]
